Publications by authors named "Juliana H Vander Pluym"
Objective: To evaluate the safety of triptans in migraine patients with cardiovascular disease or elevated cardiovascular risk.
Patients And Methods: We retrieved data from a multistate US-based health system (January 2000 to August 2022) on adults with migraine and confirmed cardiovascular/cerebrovascular disease, or at least two cardiovascular risk factors. We compared the effect of triptans to nontriptan treatments on major adverse cardiovascular events (MACE) and its components at 60 days of starting treatments.
Sequential administration of peripheral nerve blocks and onabotulinumtoxinA for the treatment of chronic migraine and other headache disorders-A retrospective tolerability and safety study.
Headache
June 2024
Objective: To determine the tolerability and safety of concurrent peripheral nerve blocks and onabotulinumtoxinA treatment during a single outpatient clinic procedure visit.
Background: Procedural interventions are available for the treatment of headache disorders. OnabotulinumtoxinA and peripheral nerve blocks are used as alternatives or in addition to oral therapies to reduce the frequency and intensity of migraine attacks.
Migraine is common in children and adolescents and can cause significant disability. There are relatively limited evidence-based treatment options available, especially when compared with treatment of migraine in adults. The Pediatric Research Equity Act requires the study of a new drug or biologic in pediatric populations.
View Article and Find Full Text PDFMigraine is a common neurological disorder that is present in a large proportion of the global population. It is estimated to occur in around 20.7% of women and 10.
View Article and Find Full Text PDFObjectives: We aimed to identify migraine treatment features preferred by patients and treatment outcomes most valued by patients.
Background: The values and preferences of people living with migraine are critical for both the choice of acute therapy and management approach of migraine.
Methods: We conducted a qualitative evidence synthesis.
Article Synopsis
- Status migrainosus (SM) is a severe migraine condition lasting over 72 hours, and the study aimed to investigate its incidence and recurrence in Olmsted County, Minnesota.
- The research identified 237 cases of SM from 2012 to 2017, predominantly affecting females, and revealed a significant incidence rate, especially among individuals aged 40-49 years.
- Stress and sleep irregularities were noted as primary triggers, with about 15% of patients experiencing recurrence within a median of 58 days, and sleep issues significantly increased the risk of recurrence.
Purpose Of Review: This review will briefly summarize recent literature published on headache disparities in underserved and vulnerable populations. It will also report the personal observations of headache medicine providers working with underserved and vulnerable populations in the USA, specifically in an urban practice dedicated to patients in a safety net program and a rural practice dedicated to Native American patients.
Recent Findings: Headache disorders are recognized as one of the most prevalent neurological conditions.
Objective: To improve the understanding of the role and utility of various neuroimaging modalities (clinical and research) for the evaluation of migraine aura (MA) and hemiplegic migraine during the ictal and interictal phases.
Background: MA is defined by reversible neurologic symptoms and is considered a manifestation of a primary condition. As such, most patients with MA do not require imaging.
Importance: Migraine is common and can be associated with significant morbidity, and several treatment options exist for acute therapy.
Objective: To evaluate the benefits and harms associated with acute treatments for episodic migraine in adults.
Data Sources: Multiple databases from database inception to February 24, 2021.
Ubrogepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist that received Food and Drug Administration (FDA) approval for the acute treatment of migraine with and without aura in adults. The ACHIEVE I and ACHIEVE II Phase III clinical trials showed that ubrogepant was superior to placebo for pain freedom and freedom of the most bothersome migraine-associated symptom at 2 hours after medication intake. The 52-week open label extension of the Phase III trials demonstrated safety of ubrogepant.
View Article and Find Full Text PDFImportance: Calcitonin gene-related peptide (CGRP) antagonists have demonstrated tremendous promise in migraine management. However, these medications decrease reflex vasodilatory response, which may lead to exacerbation of microvascular disease in susceptible patients, such as patients with Raynaud phenomenon (RP).
Objective: To investigate the microvascular complications of CGRP antagonists in patients with underlying RP.
Objective: To equip clinicians with recommendations specific to concerns related to the novel coronavirus disease 2019 (COVID-19), which impact the physical, emotional, and social health of youth with headache disorders.
Background: COVID-19 has affected societies on a global scale including children and youth with chronic headache disorders. Many concerns are predicted to arise in the 2020-2021 school year, whether classes are conducted in-person or virtually.
Objective: To summarize the current literature on non-steroidal anti-inflammatory drug and corticosteroid use during the coronavirus disease 2019 (COVID-19) pandemic, recognizing that these are commonly used treatments in the field of headache medicine.
Background: The use of non-steroidal anti-inflammatory drugs and corticosteroids in patients during the COVID-19 pandemic has been a controversial topic within the medical community and international and national health organizations. Lay press and social media outlets have circulated opinions on this topic despite the fact that the evidence for or against the use of these medications is sparse.